Calculate your body mass index (BMI)

Weight

Feet

Inches

Your BMI

Back to list

Alzheimer's Disease 227396


Study Dates: 4/12/17 - 6/30/17

Study Number

227396

Group

●  Alzheimer's Disease

Compensation

Up to: $5,335

Gender

Male, Female, Non-Smoker

Age

56 years or older

Details

This study requires that participating/eligible volunteers be diagnosed with mild cognitive impairment/Alzheimer's Disease and currently taking 10mg dose of donepezil daily for at least 30 days prior to screening visit. You will undergo an evaluation during 1 Screening visit to help determine your eligibility. In the MCI and AD part of the study, there will be two treatment periods. You will have a screening visit to see if you qualify. Once all screening evaluations have been completed (which could take up to 28 days, you will be in the study for approximately 73 days(± 2 days). This will include two treatment periods, a washout period between treatment periods (period for the study drug to be removed from your body), and a follow-up visit or phone call. You will have an in-house stay of 3 days and 2 nights at the start and end of each treatment period and an outpatient visit after taking study drug for 10 days. There will be a washout period of at least 21 days between the end of dosing for the first period and the start of dosing for the second period.